Onxeo SA
Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops novel and first-in-class DNA-decoy therapies targeting proteins in tumors and inflammatory disease processes. The company develops developing VIO-01, which is in Phase 1/2 of the VIO-01 clinical study, a Pan-DDR DNA decoy targeting multiple proteins and repair pathways in preclinical development; an… Read more
Market Cap & Net Worth: Onxeo SA (C4X)
Onxeo SA (F:C4X) has a market capitalization of $62.55 Million (€60.93 Million) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #21259 globally and #2309 in its home market, demonstrating a -3.56% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Onxeo SA's stock price €0.12 by its total outstanding shares 499448301 (499.45 Million).
Onxeo SA Market Cap History: 2015 to 2026
Onxeo SA's market capitalization history from 2015 to 2026. Data shows change from $1.88 Billion to $62.55 Million (-27.86% CAGR).
Onxeo SA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Onxeo SA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
23.70x
Onxeo SA's market cap is 23.70 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.88 Billion | $3.48 Million | -$19.41 Million | 540.36x | N/A |
| 2016 | $1.27 Billion | $4.42 Million | -$22.67 Million | 286.12x | N/A |
| 2017 | $548.56 Million | $9.51 Million | -$59.07 Million | 57.71x | N/A |
| 2018 | $433.46 Million | $6.13 Million | -$9.40 Million | 70.75x | N/A |
| 2019 | $263.00 Million | $4.29 Million | -$33.73 Million | 61.33x | N/A |
| 2020 | $340.41 Million | $1.78 Million | $1.09 Million | 191.67x | 312.59x |
| 2021 | $209.17 Million | $4.06 Million | -$5.94 Million | 51.49x | N/A |
| 2022 | $62.03 Million | $1.44 Million | -$19.56 Million | 42.99x | N/A |
| 2023 | $77.67 Million | $1.80 Million | -$20.34 Million | 43.15x | N/A |
| 2024 | $42.50 Million | $1.79 Million | -$23.93 Million | 23.70x | N/A |
Competitor Companies of C4X by Market Capitalization
Companies near Onxeo SA in the global market cap rankings as of March 18, 2026.
Key companies related to Onxeo SA by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Onxeo SA Historical Marketcap From 2015 to 2026
Between 2015 and today, Onxeo SA's market cap moved from $1.88 Billion to $ 62.55 Million, with a yearly change of -27.86%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €62.55 Million | -14.08% |
| 2025 | €72.80 Million | +71.29% |
| 2024 | €42.50 Million | -45.28% |
| 2023 | €77.67 Million | +25.21% |
| 2022 | €62.03 Million | -70.34% |
| 2021 | €209.17 Million | -38.55% |
| 2020 | €340.41 Million | +29.43% |
| 2019 | €263.00 Million | -39.33% |
| 2018 | €433.46 Million | -20.98% |
| 2017 | €548.56 Million | -56.66% |
| 2016 | €1.27 Billion | -32.71% |
| 2015 | €1.88 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Onxeo SA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $62.55 Million USD |
| MoneyControl | $62.55 Million USD |
| MarketWatch | $62.55 Million USD |
| marketcap.company | $62.55 Million USD |
| Reuters | $62.55 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.